Standard
Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. / Dalgard, Olav; Bjøro, Kristian; Larsen, Helmer Ring; Bjornsson, Einar; Holberg-Petersen, Mona; Skovlund, Eva; Reichard, Olle; Myrvang, Bjørn; Sundelöf, Bo; Ritland, Ståle; Hellum, Kjell; Frydén, Aril; Florholmen, Jon; Verbaan, Hans.
In:
Hepatology, Vol. 47, No. 1, 2008, p. 35-42.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Dalgard, O, Bjøro, K, Larsen, HR, Bjornsson, E, Holberg-Petersen, M, Skovlund, E, Reichard, O, Myrvang, B, Sundelöf, B, Ritland, S, Hellum, K, Frydén, A, Florholmen, J & Verbaan, H 2008, '
Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response',
Hepatology, vol. 47, no. 1, pp. 35-42.
https://doi.org/10.1002/hep.21975APA
Dalgard, O., Bjøro, K., Larsen, H. R., Bjornsson, E., Holberg-Petersen, M., Skovlund, E., Reichard, O., Myrvang, B., Sundelöf, B., Ritland, S., Hellum, K., Frydén, A., Florholmen, J., & Verbaan, H. (2008).
Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response.
Hepatology,
47(1), 35-42.
https://doi.org/10.1002/hep.21975Vancouver
Dalgard O, Bjøro K, Larsen HR, Bjornsson E, Holberg-Petersen M, Skovlund E et al.
Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response.
Hepatology. 2008;47(1):35-42.
https://doi.org/10.1002/hep.21975Author
Dalgard, Olav ; Bjøro, Kristian ; Larsen, Helmer Ring ; Bjornsson, Einar ; Holberg-Petersen, Mona ; Skovlund, Eva ; Reichard, Olle ; Myrvang, Bjørn ; Sundelöf, Bo ; Ritland, Ståle ; Hellum, Kjell ; Frydén, Aril ; Florholmen, Jon ; Verbaan, Hans. / Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. In: Hepatology. 2008 ; Vol. 47, No. 1. pp. 35-42.
Bibtex
@article{ce232e80ff5811ddb05e000ea68e967b,
title = "Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response",
keywords = "Former Faculty of Pharmaceutical Sciences",
author = "Olav Dalgard and Kristian Bj{\o}ro and Larsen, {Helmer Ring} and Einar Bjornsson and Mona Holberg-Petersen and Eva Skovlund and Olle Reichard and Bj{\o}rn Myrvang and Bo Sundel{\"o}f and St{\aa}le Ritland and Kjell Hellum and Aril Fryd{\'e}n and Jon Florholmen and Hans Verbaan",
year = "2008",
doi = "10.1002/hep.21975",
language = "English",
volume = "47",
pages = "35--42",
journal = "Hepatology",
issn = "0270-9139",
publisher = "JohnWiley & Sons, Inc.",
number = "1",
}
RIS
TY - JOUR
T1 - Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response
AU - Dalgard, Olav
AU - Bjøro, Kristian
AU - Larsen, Helmer Ring
AU - Bjornsson, Einar
AU - Holberg-Petersen, Mona
AU - Skovlund, Eva
AU - Reichard, Olle
AU - Myrvang, Bjørn
AU - Sundelöf, Bo
AU - Ritland, Ståle
AU - Hellum, Kjell
AU - Frydén, Aril
AU - Florholmen, Jon
AU - Verbaan, Hans
PY - 2008
Y1 - 2008
KW - Former Faculty of Pharmaceutical Sciences
U2 - 10.1002/hep.21975
DO - 10.1002/hep.21975
M3 - Journal article
VL - 47
SP - 35
EP - 42
JO - Hepatology
JF - Hepatology
SN - 0270-9139
IS - 1
ER -
